Journal of Public Health

, Volume 16, Issue 5, pp 361–367

Assessment of global cardiovascular risk and risk factors in Portugal according to the SCORE® model

  • Sofia de Oliveira Martins
  • Polybio Serra e Silva
  • Ana Luisa Papoila
  • Margarida Caramona
  • Jan W. Foppe van Mil
  • José Cabrita
Original Article

Abstract

Background/objective

Cardiovascular diseases (CVD) are the leading cause of mortality in European countries. This study aimed at estimating the 10-year risk of fatal CVD in Portuguese adults and to assess the prevalence of major cardiovascular risk factors, according to the SCORE® risk prediction system.

Subjects and methods

A cross-sectional survey was carried out in 60 community pharmacies (CP) from October 2005 to January 2006 in a sample of CP users (≥40 and ≤65 years). Data were collected by patient interviews using a structured questionnaire applied by a trained pharmacist.

Results

A total of 1,043 individuals were enrolled in the study (participation rate: 91%). The mean age was 53.7 years (SD: 7.1) with a ratio men/women of 0.68. The average risk in the sample was 1.94 (minimum 0, maximum 28, SD =2.69). About 20% of the studied adults were at high risk, of which 39.4% were asymptomatic. CV risk was significantly higher in the oldest age group and in men (p < 0.05). The prevalence of main CV risk factors was: hypertension-54.8%; hypercholesterolemia-63.1%, diabetes-13.4%; smoking-10.4% and obesity–29.0%. About 1/3 of those asked had family history of premature CVD. Mean values of biochemical and clinical parameters were: systolic blood pressure (mmHg): 134.8 ± 19.7; diastolic blood pressure (mmHg): 81.0 ± 11.4; total cholesterol (mg/dl): 193.8 ± 34.6; body mass index (kg/m2): 28.0 ± 4.5.

Conclusions

According to SCORE®, about one-fifth of the individuals was classified as high risk, and 7.7% was asymptomatic. CV risk was significantly higher in the oldest age group (55–65 years old) and in men (p < 0.05). These results show a high prevalence of some risk factors, particularly hypertension and hypercholesterolemia.

Keywords

Cardiovascular risk estimation Cardiovascular risk factors Epidemiology Portugal SCORE® risk chart 

References

  1. Amariles P, Machuca M, Jimenez-Faus A, Silva-Castro MM, Sabater D, Baena MI et al (2004) Cardiovascular risk: components, evaluation and preventative interventions. Ars Pharmaceutica 45(3):187–210Google Scholar
  2. Atthobari J, Monster TB, De Jong PE, De Jong-van den Berg LT (2004) Prevention Study Group-The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs. Br J Clin Pharmacol 57(3):328–36PubMedCrossRefGoogle Scholar
  3. Buitrago F, Canon-Barroso L, Diaz-Herrera N, Cruces-Muro E, Escober-Fernandez M, Serrano-Arias JM (2007) Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment. Rev Esp Cardiol 60(2):139–47PubMedCrossRefGoogle Scholar
  4. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al (2003) Estimation of ten-year of fatal cardiovascular disease in Europe: SCORE project. Eur Heart J 24:987–1003PubMedCrossRefGoogle Scholar
  5. Costa J, Borges M, Oliveira E, Gouveia M, Vaz Carneiro A (2003) Incidence and Prevalence of Hypercholesterolemia in Portugal: a systematic review. Part III. Rev Port Cardiol 22(6):829–836Google Scholar
  6. De Macedo ME, Lima MJ, Silva AO, Alcantara P, Ramalhinho V, Carmona J (2007) Prevalence, awareness, treatment and control of hypertension in Portugal. The PAP study. Rev Port Cardiol 26(1):21–39PubMedGoogle Scholar
  7. European guidelines on cardiovascular prevention in clinical practice (2003) Eur J Cardiovasc Prev Rehabil 10(suppl 1):1–78Google Scholar
  8. Expert Panel on the Identification, Evaluation and Treatment of Overweight in adults (1998) Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr 68:899–917Google Scholar
  9. Fornasini M, Brotons C, Sellares J, Martinez M, Galan ML, Saenz I et al (2006) Consequences of using different methods to access cardiovascular risk in primary care. Fam Pract 23(1):28–33PubMedCrossRefGoogle Scholar
  10. Getz L, Sigurdsson JA, Hetlevik I, Kirkengen AL, Romundstad S, Holmen J (2005) Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: Modelling study. Br Med J 331:551–554CrossRefGoogle Scholar
  11. Gonzalez C, Rodilla E, Costa JA, Justicia J, Pascual JM (2006) Cardiovascular risk by Framingham and SCORE in patients 40–65 years old. Med Clin (Barc) 126(14):535–356CrossRefGoogle Scholar
  12. Hourihan F, Krass I, Chen T (2003) Rural community pharmacy: a feasible site for a health promotion and screening service for cardiovascular risk factors. Aus J Rural Health 11(1):28–35CrossRefGoogle Scholar
  13. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H et al (2000) Estimation of contribution of changes in classic risk factors to trends in coronary event rates across the WHO MONICA Project populations. Lancet 355:375–387CrossRefGoogle Scholar
  14. Mangum SA, Kraenow KR, Narducci WA (2003) Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc (Wash) 43(1):50–55CrossRefGoogle Scholar
  15. Marrugat J, D’Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J et al (2003) An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 57:634–638PubMedCrossRefGoogle Scholar
  16. Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A (2005) European cardiovascular disease statistics. BHF, LondonGoogle Scholar
  17. Quaglini S, Stefanelli M, Boiocchi L, Campari F, Cavallini A, Micieli G (2005) Cardiovascular risk calculators: understanding differences and realising economic implications. Int J Med Inform 74(2–4):191–199PubMedCrossRefGoogle Scholar
  18. Santos AC, Barros H (2003) Prevalence and determinants of obesity in an urban sample of Portuguese adults. Public Health 117(6):430–437PubMedCrossRefGoogle Scholar
  19. Sarti C, Rastenyte D, Capaitis Z, Tuomilehto J (2000) International trends in mortality from stroke, 1968 to 1994. Stroke 31(7):1588–601PubMedGoogle Scholar
  20. Schindler C, Bramlage P, Thoenes M, Bramlage C, Kirch W (2007) Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs. Clin Drug Investig 27(10):707–717PubMedCrossRefGoogle Scholar
  21. Scholte op Reimer WJ, Moons P, De Geest S, Fridlund B, Heikkila J, Jaarsma T et al (2006) Cardiovascular risk estimation by professionally active cardiovascular nurses: results from the Basel 2005 Nurses Cohort. Eur J Cardiovasc Nurs 5(4):258–263PubMedCrossRefGoogle Scholar
  22. Simon A, Mijiti W, Gariepy J, Levenson J (2006) Current possibilities for detecting high risk of cardiovascular disease. Int J Cardiol 110(2):146–152PubMedCrossRefGoogle Scholar
  23. Snella KA, Canales AE, Irons BK, Sleeper-Irons RB, Villarreal MC, Levi-Derrick VE et al (2006) Pharmacy and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc (Wash DC) 46(3):370–377Google Scholar
  24. World Health Organization. International Society of Hypertension. Guidelines for the management of hypertension (1999) Guidelines Subcommittee. J Hypertens 17:151–183Google Scholar
  25. WHO Regional Publications (2002) The European Health report. WHO Europe. European Series, CopenhagenGoogle Scholar
  26. WHO Regional Publications (2005) European Cardiovascular disease statistics-2005 edition. WHO Europe. European Series, CopenhagenGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Sofia de Oliveira Martins
    • 1
    • 2
  • Polybio Serra e Silva
    • 3
    • 4
  • Ana Luisa Papoila
    • 5
  • Margarida Caramona
    • 6
  • Jan W. Foppe van Mil
    • 7
  • José Cabrita
    • 1
    • 2
  1. 1.Faculdade de Farmácia da Universidade de LisboaLisboaPortugal
  2. 2.IMed.ULLisbonPotugal
  3. 3.Faculty of MedicineUniversity of CoimbraCoimbraPortugal
  4. 4.Portuguese Foundation of CardiologyLisbonPortugal
  5. 5.Faculty of Medical Sciences-U. NovaLisbonPortugal
  6. 6.Faculty of PharmacyUniversity of CoimbraCoimbraPortugal
  7. 7.van Mil ConsultancyZuidlarenThe Netherlands

Personalised recommendations